Clinical-stage biopharmaceutical company developing immunotherapies for rare diseases and cancer by harnessing and targeting regulatory T cells (Tregs)
Clinical-stage biopharmaceutical company developing immunotherapies for rare diseases and cancer by harnessing and targeting regulatory T cells (Tregs). Its pipeline includes RGI-2001, a small-molecule and liposome-based treatment designed to expand Tregs for graft-versus-host disease (GvHD), and antibody therapeutics intended to reduce Treg-mediated immune suppression in tumors.